Insider Selling: Hims & Hers Health (NYSE:HIMS) COO Sells 14,027 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 14,027 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the sale, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hims & Hers Health Stock Performance

HIMS traded up $0.50 during trading on Wednesday, hitting $31.97. The stock had a trading volume of 23,080,110 shares, compared to its average volume of 30,466,682. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The firm has a market capitalization of $7.40 billion, a P/E ratio of -355.22, a PEG ratio of 56.60 and a beta of 2.37. The company’s 50-day moving average price is $25.87 and its 200 day moving average price is $26.65. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted $0.20 EPS. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently modified their holdings of HIMS. Farallon Capital Management LLC boosted its position in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. BIT Capital GmbH boosted its position in Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after purchasing an additional 938,728 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Hims & Hers Health by 25.6% in the 4th quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock worth $12,064,000 after buying an additional 75,679 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Finally, CI Investments Inc. boosted its position in shares of Hims & Hers Health by 6,659.7% in the 3rd quarter. CI Investments Inc. now owns 206,510 shares of the company’s stock worth $11,713,000 after buying an additional 203,455 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. TD Cowen lowered their price objective on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Canaccord Genuity Group set a $32.00 price target on Hims & Hers Health in a research note on Tuesday, May 12th. Barclays restated an “overweight” rating and issued a $39.00 price target on shares of Hims & Hers Health in a research note on Wednesday. Leerink Partners lifted their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research note on Monday, March 16th. Finally, Zacks Research downgraded Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, June 8th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $29.37.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.